Pharmacotherapy coronary interventions: new insights
<p class="moderator speaker-name">Anchorperson: <span classs="personname">Davide Capodanno</span></p><p class="moderator speaker-name">Spokesperson: <span classs="personname">Fazila Malik</span></p><p class="moderator speaker-name">Discussants: <span classs="personname">Harlan Krumholz, Marco Valgimigli, Franz Weidinger</span></p>
<div class="intervention"><div class="interventionTitle">Ticagrelor monotherapy in chronic coronary syndrome patients post percutaneous coronary intervention</div><p class="speaker-intervention-name-img">Javad Kojuri</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Multiple events after PCI in patients at high bleeding risk: a MASTER DAPT trial sub-analysis</div><p class="speaker-intervention-name-img">Marco Valgimigli</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Effect of BB interruption on blood pressure in MI patients: secondary results of the ABYSS trial</div><p class="speaker-intervention-name-img">Niki Procopi</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div><div class="intervention"><div class="interventionTitle">Long-term outcomes of 3-to 6-month versus 12-month DAPT after PCI with contemporary stents</div><p class="speaker-intervention-name-img">Hyo-Soo Kim</p></div><div class="intervention"><div class="interventionTitle">Discussion and audience interaction</div></div>